Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5537)
All Articles published online
|
Publishing Process of This Article
|
Sep 16, 2021 (publication date) through May 27, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Guo CX, Huang X, Xu J, Zhang XZ, Shen YN, Liang TB, Bai XL. Combined targeted therapy and immunotherapy for cancer treatment. World J Clin Cases 2021; 9(26): 7643-7652 [PMID: 34621816 DOI: 10.12998/wjcc.v9.i26.7643] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v9/i26/7643.htm |
| Number | Citing Articles |
| 1 |
Si-Cong Chen, Dong-Heng Ma, Jia-Jian Zhong. Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report. World Journal of Clinical Cases 2023; 11(27): 6579-6586 doi: 10.12998/wjcc.v11.i27.6579
Abstract(649) |
Core Tip(468) |
Full Article(HTML)(1177)
|
Full Article with Cover (PDF)-19348K(148)
|
Full Article (Word)-1830K(21)
|
Audio-348K(2)
|
Peer-Review Report-223K(62)
|
Answering Reviewers-333K(54)
|
Full Article (PDF)-19049K(90)
|
Full Article (XML)-59K(59)
|
Times Cited (0)
|
Total Visits (4118)
|
Open
|
| 2 |
Gaoyuan Yang, Yupeng Ren, Yuxuan Li, Yongchang Tang, Feng Yuan, Mingbo Cao, Zhiwei He, Xiaorui Su, Zheng Shi, Ziyi Hu, Meihai Deng, Jie Ren, Zhicheng Yao. Post-treatment adverse events ranking in targeted immunotherapy for hepatocellular carcinoma: A network meta-analysis based on risk probability assessment. Critical Reviews in Oncology/Hematology 2025; 211: 104737 doi: 10.1016/j.critrevonc.2025.104737
|
| 3 |
Giandomenico Roviello, Melissa Bersanelli, Martina Catalano. The Latest Developments in Biomarkers Predicting Response to Immunotherapy. Immunotherapy 2022; 14(14): 1085 doi: 10.2217/imt-2022-0053
|
| 4 |
Fatemah S. Basingab, Manar Bashanfer, Aisha A. Alrofaidi, Ahmed S. Barefah, Rawan Hammad, Hadil M. Alahdal, Jehan S. Alrahimi, Kawther A. Zaher, Sabah Hassan, Ali H. Algiraigri, Mai M. El-Daly, Saleh A. Alkarim, Alia M. Aldahlawi. T-Cell Immunoglobulin and Mucin Domain 3 (TIM-3) Gene Expression as a Negative Biomarker of B-Cell Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences 2024; 25(20): 11148 doi: 10.3390/ijms252011148
|
| 5 |
Lisa Schlicher, Luke G. Green, Andrea Romagnani, Florian Renner. Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status. Frontiers in Immunology 2023; 14 doi: 10.3389/fimmu.2023.1297175
|
| 6 |
Amrita Arup Roy, Rahul Pokale, Anoushka Mukharya, Sandesh Ramchandra Jadhav, Gaurisha Alias Resha Ramnath Naik, S. P. Rachana, Viola Colaco, Paniz Hedayat, Ritu Kudarha, Srinivas Mutalik, Namdev Dhas. Core-Shell Nano Constructs for Cancer Theragnostic. 2025; : 415 doi: 10.1007/978-981-96-3025-7_15
|
| 7 |
Kiran Kumar Kolathur, Radhakanta Nag, Prathvi V Shenoy, Yagya Malik, Sai Manasa Varanasi, Ramcharan Singh Angom, Debabrata Mukhopadhyay. Molecular Susceptibility and Treatment Challenges in Melanoma. Cells 2024; 13(16): 1383 doi: 10.3390/cells13161383
|
| 8 |
Manjeera Ramadas, Nikhitha Jacob, Malaka Ameratunga, Lucy Gately. Unlocking therapeutic synergy: IDH inhibitors and immunotherapy combination in preclinical and clinical IDH mutant glioma models − A systematic review. Journal of Clinical Neuroscience 2025; 136: 111281 doi: 10.1016/j.jocn.2025.111281
|
| 9 |
Mariana Neves Amaral, Pedro Faísca, Hugo Alexandre Ferreira, Maria Manuela Gaspar, Catarina Pinto Reis. Current Insights and Progress in the Clinical Management of Head and Neck Cancer. Cancers 2022; 14(24): 6079 doi: 10.3390/cancers14246079
|
| 10 |
Sai Manasa Varanasi, Yash Gulani, Hari Krishnareddy Rachamala, Debabrata Mukhopadhyay, Ramcharan Singh Angom. Neuropilin-1: A Multifaceted Target for Cancer Therapy. Current Oncology 2025; 32(4): 203 doi: 10.3390/curroncol32040203
|
| 11 |
Mina Rezghi Rami, Maryam Meskini, Mohammed A. E. Elmakki. Biotechnology and Cancer Therapeutics. Interdisciplinary Biotechnological Advances 2025; : 291 doi: 10.1007/978-981-96-4959-4_10
|
| 12 |
Yong-Po Zhang, Yue-Wei Tian, Jiang Geng, Xin-Hui Zhou, Meng-Ze Li, Guang-Huan Liu, Chun-Yan Gao, Ai-Qin Yue, Jin-Zhong Zhao, Wei-Jun Du. Nattokinase enhances the sensitivity of cancer cells to oxaliplatin through mitochondrial pathway and induction of apoptosis. Arabian Journal of Chemistry 2024; 17(1): 105478 doi: 10.1016/j.arabjc.2023.105478
|
| 13 |
Rose Ghemrawi, Lama Abuamer, Sedra Kremesh, Ghadeer Hussien, Rahaf Ahmed, Walaa Mousa, Ghalia Khoder, Mostafa Khair. Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Biomedicines 2024; 12(9): 2158 doi: 10.3390/biomedicines12092158
|
| 14 |
Xiaoya Guan, Huina Guo, Yujia Guo, Qi Han, Zhongxun Li, Chunming Zhang. Perforin 1 in Cancer: Mechanisms, Therapy, and Outlook. Biomolecules 2024; 14(8): 910 doi: 10.3390/biom14080910
|
| 15 |
Pankaj Garg, Siddhika Pareek, Prakash Kulkarni, David Horne, Ravi Salgia, Sharad S. Singhal. Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment. Journal of Clinical Medicine 2024; 13(21): 6537 doi: 10.3390/jcm13216537
|
| 16 |
Lingyu Li, Yingli Sun. Challenges and advances of immune checkpoint therapy. Clinical and Translational Discovery 2024; 4(6) doi: 10.1002/ctd2.70001
|
| 17 |
Poulami Sarkar, Manami Sardar, Olivia Sen, Stabak Das, Sreejan Manna. Therapeutic Efficacy of Nanocarrier‐Mediated Inhalable Gene Transfection for Lung Cancer. ChemistrySelect 2024; 9(37) doi: 10.1002/slct.202402903
|